HIV

The Pharmacy Times® human immunodeficiency virus (HIV) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
As patients with HIV are living longer, they are also being diagnosed with chronic conditions that have become increasingly common in recent decades, putting them at higher risk of COVID-19 hospitalization and death.
 
[[thumbnail_alt_text]]
At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.
[[thumbnail_alt_text]]
The FDA has approved Rukobia (fostemsavir) for the treatement of human immunodeficiency virus 1 (HIV-1) infection. 
[[thumbnail_alt_text]]
Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.
[[thumbnail_alt_text]]
Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
[[thumbnail_alt_text]]
Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
[[thumbnail_alt_text]]
The US Department of Health & Human Services released guidance at the beginning of the pandemic clarifying guidelines regarding best practices in HIV care.
[[thumbnail_alt_text]]
This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.
[[thumbnail_alt_text]]
Conduct proper review and evaluation of ARV and DOAC pharmacokinetics and metabolism prior to recommending treatment.
[[thumbnail_alt_text]]
Although HIV self-tests are available for retail purchase by consumers, the CDC encourages health departments to consider self-testing as an additional strategy to reach individuals most affected by the virus.
[[thumbnail_alt_text]]
This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.
[[thumbnail_alt_text]]
Insurance companies are currently investigating the option of modifying which medications they will cover for HIV pre-exposure prophylaxis (PrEP) therapy, with broad implications for patient access.